cPLA2–Inhibitor (stoPLA) – New compounds for the topical treatment of skin inflammation
Novel group of nonsteroidal anti-inflammatory drugs: The new class of heteroaryl-substituted acetone derivatives inhibits effectively the cytosolic phospholipase A2 (cPLA2).
The compounds interact with the synthesis of prosta-glandins and leukotrienes and reduce inflammatory processes. The substances have an excellent solubility profile. The heteroaryl-substituted acetone derivatives provide the platform for the development of new pharmaceutical products for the treatment of inflammatory diseases of the skin, such as psoriasis and atopic dermatitis.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
NASA: Mystery of life’s handedness deepens
The mystery of why life uses molecules with specific orientations has deepened with a NASA-funded discovery that RNA — a key molecule thought to have potentially held the instructions for…
What are the effects of historic lithium mining on water quality?
Study reveals low levels of common contaminants but high levels of other elements in waters associated with an abandoned lithium mine. Lithium ore and mining waste from a historic lithium…
Quantum-inspired design boosts efficiency of heat-to-electricity conversion
Rice engineers take unconventional route to improving thermophotovoltaic systems. Researchers at Rice University have found a new way to improve a key element of thermophotovoltaic (TPV) systems, which convert heat…